Table 1. Demographic data of patients receiving TKI as first-, or second-line therapy.

Characteristic	First-line TKI (n = 264)	Second-line TKI (n = 187)	P
Median age (range)	63 (32–86)	61 (30–81)
≥ 60	164 (62.1%)	103 (55.1%)	0.134
< 60	100 (37.9%)	84 (44.9%)
Gender
Male	103 (39.0%)	84 (44.9%)	0.210
Female	161 (61.0%)	103 (55.1%)
Smoking status
Smoker	58 (22.0%)	45 (24.1%)	0.602
Never-smoker	206 (78.0%)	142 (75.9%)
Histology
Adeno	249 (94.3%)	161 (86.1 %)	0.003
Others	15 (5.7%)	26 (13.9%)
Types of EGFR TKI
Erlotinib	68 (25.8%)	38 (20.3%)	0.031
Gefitinib	147 (55.7%)	95 (50.8%)
Icotinib	49 (18.6%)	54 (28.9%)
Mutation type
19 del	145 (54.9%)	94 (50.3%)	0.329
21 L858R	119 (45.1%)	93 (49.7%)
PS
0–1	242 (91.7%)	183 (97.9%)	0.021
≥ 2	18 (6.8%)	4 (2.1%)

Abbreviation: TKI, tyrosine kinase inhibitor.